BGBIO: BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
2022-01-27 07:00:16
Bergen/Oslo, Norway 27 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs and Oslo University Hospital announced today the execution
of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib,
in hospitalised COVID-19 patients.
The EU-SolidAct trial - European DisCoVeRy for Solidarity: An Adaptive Pandemic
and Emerging Infection Platform Trial - is part of EU-RESPONSE, a pan-European
research project involved withthe rapid and coordinated investigation of
medicationsto treat COVID-19 during the ongoing pandemic. The EU-SolidAct
(EudraCT: 2021-000541-41